Walleye Capital
VRTX icon

Walleye Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Walleye Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.46M Sell
5,500
-2,400
-30% -$1.12M 0.01% 1302
2025
Q4 		$3.58M Buy
7,900
+1,100
+16% +$474K 0.01% 1404
2025
Q3 		$2.66M Sell
6,800
-5,900
-46% -$2.47M 0.01% 1369
2025
Q2 		$5.65M Sell
12,700
-1,300
-9% -$599K 0.02% 801
2025
Q1 		$6.79M Buy
14,000
+6,900
+97% +$3.22M 0.03% 626
2024
Q4 		$2.86M Sell
7,100
-10,600
-60% -$4.91M 0.01% 1457
2024
Q3 		$8.23M Buy
17,700
+1,900
+12% +$913K 0.02% 816
2024
Q2 		$7.41M Sell
15,800
-15,200
-49% -$6.6M 0.01% 976
2024
Q1 		$13M Buy
31,000
+27,300
+738% +$11.5M 0.02% 669
2023
Q4 		$1.51M Sell
3,700
-3,800
-51% -$1.4M ﹤0.01% 2010
2023
Q3 		$2.61M Hold
7,500
– – 0.01% 1524
2023
Q2 		$2.64M Sell
7,500
-900
-11% -$303K 0.01% 1142
2023
Q1 		$2.65M Buy
8,400
+2,100
+33% +$630K 0.04% 563
2022
Q4 		$1.82M Buy
6,300
+4,900
+350% +$1.49M 0.03% 637
2022
Q3 		$405K Buy
+1,400
New +$403K 0.01% 1615
2020
Q1 		– Sell
-31,100
Closed -$6.81M – 1726
2019
Q4 		$6.81M Sell
31,100
-57,500
-65% -$11.6M 0.44% 22
2019
Q3 		$15M Buy
88,600
+61,200
+223% +$10.8M 0.89% 3
2019
Q2 		$5.03M Buy
27,400
+17,100
+166% +$2.99M 0.55% 12
2019
Q1 		$1.9M Buy
+10,300
New +$1.9M 0.31% 49

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Walleye Capital's VRTX Position: Q1 2026 in Review

Walleye Capital increased its Vertex Pharmaceuticals (VRTX) stake by 105% in Q1 2026, buying an estimated $7.36M and bringing the position to 30,752 shares worth $13.7M. The position accounts for 0.06% of the portfolio, ranked #291.

Walleye Capital first reported a position in VRTX in Q1 2019 and has held it in 26 quarters since. The position peaked at $19.4M in Q3 2022. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Walleye Capital held 30,752 shares of Vertex Pharmaceuticals worth $13.7M as of Q1 2026.
  • Walleye Capital bought 15,778 Vertex Pharmaceuticals shares in Q1 2026, an estimated $7.36M.
  • Vertex Pharmaceuticals made up 0.06% of Walleye Capital's portfolio in Q1 2026, its #291 holding.
  • Walleye Capital first reported a position in Vertex Pharmaceuticals in Q1 2019 and has held it in 26 quarters since.
  • Walleye Capital's Vertex Pharmaceuticals position peaked at $19.4M in Q3 2022.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.